Preclinical studies with U3-1287 demonstrate tumor inhibition in A549 model and partial inhibition in FaDu model, suggesting the antibody might be more effective against HER2+/EGFR+ amplified models relative to the NRG driven models. This evidence concerns the gene EGFR and neoplasm.